Cost-effectiveness analysis of vaccination against COVID-19 in China

被引:2
|
作者
Zhou, Huixuan [1 ,2 ]
Ding, Ningxin [3 ]
Han, Xueyan [4 ]
Zhang, Hanyue [5 ]
Liu, Zeting [6 ]
Jia, Xiao [2 ]
Yu, Jingjing [2 ]
Zhang, Wei [7 ]
机构
[1] Beijing Sport Univ, Sch Sport Sci, Dept Phys Fitness & Hlth, Beijing, Peoples R China
[2] Beijing Sport Univ, Key Lab Exercise & Phys Fitness, Minist Educ, Beijing, Peoples R China
[3] Victoria Univ Wellington, Sch Govt, Wellington Sch Business & Govt, Wellington, New Zealand
[4] Chinese Acad Med Sci & Peking Union Med Coll, Sch Hlth Policy & Management, Beijing, Peoples R China
[5] North East Normal Univ, Sch Phys Educ, Jilin, Peoples R China
[6] Beijing Sport Univ, Sch Sport Engn, Dept Math Sci, Beijing, Peoples R China
[7] China Natl Inst Food & Drug Control, Dept Chem Drug Control, Beijing, Peoples R China
关键词
COVID-19; vaccination; cost-effectiveness analysis; cost-utility analysis; SARS-CoV-2; ECONOMIC VALUE; HEALTH;
D O I
10.3389/fpubh.2023.1037556
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
IntroductionSince September 2020, Chinese populations aged > 3 years have been encouraged to receive a two-dose inoculation with vaccines against coronavirus disease 2019 (COVID-19). This study aims to evaluate the cost-effectiveness of the current vaccination strategy amongst the general population in mainland China from a societal perspective. MethodsIn this study, we construct a decision tree with Markov models to compare the economic and health consequences of the current vaccination strategy versus a no-vaccination scenario, over a time horizon of one year and an annual discount rate of 5%. Transition probabilities, health utilities, healthcare costs, and productivity losses are estimated from literature. Outcome measures include infection rates, death rates, quality-adjusted life years (QALYs), and costs. The incremental cost-effectiveness ratio (ICER) is then calculated to evaluate the cost-effectiveness of the current vaccination strategy, and both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis (PSA) are applied to assess the impact of uncertainties on results. ResultsOur simulation indicates that compared with a no-vaccination scenario, vaccination amongst the general population in mainland China would reduce the infection rate from 100% to 45.3% and decrease the death rate from 6.8% to 3.1%. Consequently, the strategy will lead to a saving of 37,664.77 CNY (US$5,256.70) and a gain of 0.50 QALYs per person per year on average (lifetime QALY and productivity loss due to immature death are included). The cost-saving for each QALY gain is 74,895.69 CNY (US$10,452.85). Result of the PSA indicates that vaccination is the dominating strategy with a probability of 97.9%, and the strategy is cost-effective with a probability of 98.5% when the willingness-to-pay (WTP) is 72,000 CNY (US$10,048.71) per QALY. ConclusionCompared with a no-vaccination scenario, vaccination among the general population in mainland China is the dominating strategy from a societal perspective. The conclusion is considered robust in the sensitivity analyses.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of COVID-19 vaccination in Poland
    Orlewska, Katarzyna
    Wierzba, Waldemar
    Sliwczynski, Andrzej
    [J]. ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (04) : 1021 - 1030
  • [2] COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey
    Hagens, Arnold
    Inkaya, Ahmet Cagkan
    Yildirak, Kasirga
    Sancar, Mesut
    van der Schans, Jurjen
    Sancar, Aylin Acar
    Unal, Serhat
    Postma, Maarten
    Yegenoglu, Selen
    [J]. VACCINES, 2021, 9 (04)
  • [3] Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
    Orangi, Stacey
    Ojal, John
    Brand, Samuel P. C.
    Orlendo, Cameline
    Kairu, Angela
    Aziza, Rabia
    Ogero, Morris
    Agweyu, Ambrose
    Warimwe, George M.
    Uyoga, Sophie
    Otieno, Edward
    Ochola-Oyier, Lynette, I
    Agoti, Charles N.
    Kasera, Kadondi
    Amoth, Patrick
    Mwangangi, Mercy
    Aman, Rashid
    Ng'ang'a, Wangari
    Adetifa, Ifedayo M. O.
    Scott, J. Anthony G.
    Bejon, Philip
    Keeling, Matt J.
    Flasche, Stefan
    Nokes, D. James
    Barasa, Edwine
    [J]. BMJ GLOBAL HEALTH, 2022, 7 (08):
  • [4] Cost-effectiveness of COVID-19 vaccination: A systematic review
    Fu, Yaqun
    Zhao, Jingyu
    Han, Peien
    Zhang, Jiawei
    Wang, Quan
    Wang, Qingbo
    Wei, Xia
    Yang, Li
    Ren, Tao
    Zhan, Siyan
    Li, Liming
    [J]. JOURNAL OF EVIDENCE BASED MEDICINE, 2023, 16 (02) : 152 - 165
  • [5] Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China
    Fu, Yaqun
    Zhao, Jingyu
    Wei, Xia
    Han, Peien
    Yang, Li
    Ren, Tao
    Zhan, Siyan
    Li, Liming
    [J]. VACCINES, 2022, 10 (10)
  • [6] Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA
    Li, Rui
    Lu, Pengyi
    Fairley, Christopher K.
    Pagan, Jose A.
    Hu, Wenyi
    Yang, Qianqian
    Zhuang, Guihua
    Shen, Mingwang
    Li, Yan
    Zhang, Lei
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (01) : 85 - 95
  • [7] Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA
    Rui Li
    Pengyi Lu
    Christopher K. Fairley
    José A. Pagán
    Wenyi Hu
    Qianqian Yang
    Guihua Zhuang
    Mingwang Shen
    Yan Li
    Lei Zhang
    [J]. Applied Health Economics and Health Policy, 2024, 22 : 85 - 95
  • [8] A cost-effectiveness analysis of South Africa's ' s COVID-19 vaccination programme
    Edoka, Ijeoma
    Silal, Sheetal
    Jamieson, Lise
    Meyer-Rath, Gesine
    [J]. VACCINE, 2024, 42 (20)
  • [9] COST-EFFECTIVENESS OF COVID-19 VACCINATION IN COLOMBIA: A MICRO-SIMULATION MODELLING ANALYSIS
    Castaneda-Orjuela, C.
    Alvis-Zakzuk, N.
    Diaz-Jimenez, D.
    Alvis-Guzman, N.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S348 - S348
  • [10] Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
    Reddy, Krishna P.
    Fitzmaurice, Kieran P.
    Scott, Justine A.
    Harling, Guy
    Lessells, Richard J.
    Panella, Christopher
    Shebl, Fatma M.
    Freedberg, Kenneth A.
    Siedner, Mark J.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)